Form 4: Iteos Therapeutics Director Tony W. Ho Acquires Stock Options
SEC Form 4
Director Tony W. Ho of iTeos Therapeutics, Inc. reports acquisition of stock options.
Summary
- On June 11, 2024, Tony W. Ho, a director of iTeos Therapeutics, Inc., acquired 24,200 stock options.
- The options have an exercise price of $16.32.
- The options become exercisable on June 11, 2025, and expire on June 11, 2034.
- Following the transaction, Mr. Ho directly owns 24,200 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director, which doesn't inherently indicate positive or negative sentiment but suggests alignment of interests.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to insider transactions, common in the biopharmaceutical industry where stock options are frequently used as part of executive compensation packages.
Stakeholder Impact
- The acquisition of stock options by a director could potentially increase shareholder confidence due to alignment of interests.
Key Dates
| Date | Description |
|---|---|
| 06/11/2024 | Date of transaction: Tony W. Ho acquired stock options. |
| 06/11/2025 | Date the stock options become exercisable. |
| 06/11/2034 | Expiration date of the stock options. |
| 06/13/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.